The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Neither UTMB nor Moderna has confirmed the nature of the project included in the announcement, or how much funding is being ...

Moderna is suing its chief competitor in the COVID-19 vaccine space, alleging that Pfizer and BioNTech stole key technology used in the development of that group's inoculation.

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

Moderna stock is worth ~39% more than BioNTech stock, which is a significant amount, but it has always been the higher valued company, and back in September 2021, it was worth 2x more than BioNTech.

Moderna is not asking that courts take the Pfizer-BioNTech COVID-19 vaccine off the market or to stop future sales, in view of the public need for the vaccines. Moderna and Pfizer's vaccines have ...

Moderna is suing Pfizer and BioNTech, alleging the companies copied its technology used to create their COVID-19 vaccine. The lawsuits were filed in Massachusetts and Germany.

Moderna said Friday, Aug. 26, 2022, that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax.

Moderna sued Pfizer and its German partner BioNTech on Friday, alleging that the rival firms improperly used its foundational technology in developing their coronavirus vaccine.